Salmeterol - Fluticasone Dry Powder Inhaler
Asthma affects over 334 million patients worldwide. Asthma and COPD are the third highest cause of death in United States currently and is expected to be the 3rd highest cause of death globally by 2020.
Inhalation drugs contribute 70% of this market. Inhaled short and long-acting beta agonists and corticosteroids are fundamental to the treatment of asthma. Dry Powder Inhalers (DPIs) containing long-acting beta agonists and inhaled corticosteroids constitute largest drug class with market share of more than 50%.
SPARC’s breath activated DPI device offers pre-metered 60 doses of Fluticasone and Salmeterol. The salient features of the device are
- Equivalent product to Seretide Diskus at half the metered dose
- Uniform dose delivery independent of inspiratory flow rate
- Device is suitable for a wide range of patients, including those with low maximal inspiratory force and severe disease